共 103 条
[1]
Siegel RL(2017)Cancer statistics, 2017 CA Cancer J Clin 67 7-30
[2]
Miller KD(2006)Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States) Cancer Causes Control 17 403-409
[3]
Jemal A(2007)Validation of the 6th edition AJCC pancreatic Cancer staging system: report from the National Cancer Database Cancer 110 738-744
[4]
Cress RD(1997)Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403-2413
[5]
Yin D(2006)Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer J Clin Oncol 24 3946-3952
[6]
Clarke L(2005)Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial J Clin Oncol 23 3509-3516
[7]
Bold R(2004)Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate J Clin Oncol 22 3776-3783
[8]
Holly EA(2007)Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the central European cooperative oncology group J Clin Oncol 25 2212-2217
[9]
Bilimoria KY(2010)Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: southwest oncology group-directed intergroup trial S0205 J Clin Oncol 28 3605-3610
[10]
Bentrem DJ(2007)Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group J Clin Oncol 25 1960-1966